Mitral Valve Prolapse (MVP) is a common heart valve condition characterized by the improper closing of the valve between the heart's upper and lower left chambers, the atrium and ventricle. In individuals with MVP, the valve's flaps, known as leaflets, bulge or collapse backward into the atrium, causing a regurgitation of blood. While many people with MVP may not experience symptoms, others may encounter chest pain, palpitations, or fatigue. The exact cause of MVP is often unknown, but it can be associated with connective tissue disorders. Diagnosis typically involves echocardiography, which allows visualization of the valve's structure and function. Treatment is often unnecessary for those without symptoms, but in severe cases, medications or, in rare instances, surgery may be recommended to repair or replace the valve. Regular monitoring and consultation with healthcare professionals are essential for managing Mitral Valve Prolapse effectively.
Title : Surgical fetal stem cells implantation in heart failure patients long term results at 14 years
Federico Benetti, Benetti Foundation, Argentina
Title : Exploring new biomarkers of cardiomyopathy
Shuping Zhong, University of Southern California, United States
Title : The development of human relaxin-2 for heart failure with preserved ejection fraction, HFpEF
Thomas Bernd Dschietzig, Relaxera GmbH & Co. KG, Germany
Title : Cancer and cardiovascular diseases: Common pathogenesis mechanisms and risk factors
Mekhman N Mamedov, National Research Center for Preventive Medicine, Russian Federation
Title : Pulse field ablation for atrial fibrillation complications: What do we know yet
Narendra Kumar, HeartbeatsZ Academy, United Kingdom
Title : Lipoprotein (a): The hidden cardiovascular risk
Syed Raza, Awali Hospital, Bahrain